NCT04842812RecruitingPhase 1
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 25 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 4 Apr 2021
- Start date
- 1 Jan 2021
- Primary completion date
- 31 Dec 2029
- Lead sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- NCT number
- NCT04842812
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- From 1 Jan 2021 to the primary completion date, 31 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Had accepted gene therapy before;
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
Other illness
- Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;
- Active infectious disease related to bacteria, virus, fungi, et al;
- Other severe diseases that the investigators consider not appropriate;
- Other conditions that the investigators consider not appropriate.
Other
- Pregnant or lactating women;
Who the study is looking for
- Patients with advanced cancers that failed to current available therapies;
- Life expectancy \>12 weeks;
- Adequate heart, lung, liver, kidney functions;
- Available for tumor biopsy or cancerous effusions;
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Affiliated Hospital of Guangzhou Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.